Utama › Karsinoma Neuroendokrin › California
Kajian klinikal Karsinoma Neuroendokrin di California
6 kajian untuk Karsinoma Neuroendokrin sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
- Los Alamitos Hematology/Oncology Medical Group, Glendale
- MemorialCare Long Beach Medical Center, Long Beach
- Valkyrie Clinical Trials, Los Angeles
- dan 2 lagi
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT07080242A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Ogo 2026 · NCT06330064A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- Crinetics Study Site, Duarte
- Crinetics Study Site, Newport Beach
- Crinetics Study Site, Orange
- dan 1 lagi
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 31 Jul 2026 · NCT07129252A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT05652686A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- St Joseph Heritage Healthcare, Santa Rosa
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Dis 2025 · NCT06943521Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.